Lineage Cell Therapeutics, Inc. (LCTX) AI Stock Analysis

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to pioneering novel cell therapies aimed at treating degenerative diseases globally. The company focuses on developing transformative treatments that address critical unmet medical needs across ophthalmology, neurology, and oncology. Its lead programs include OpRegen, a retinal pigment epithelium cell replacement therapy in Phase I/IIa clinical trials for dry age-related macular degeneration. Lineage is also advancing OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa multicenter trials for acute spinal cord injuries, and VAC2, an allogeneic dendritic cell cancer immunotherapy in Phase I trials for non-small cell lung cancer.

Revenue increased at a 5-year CAGR of 79.9% between FY2020 and FY2025, reaching $14.6M in FY2025 after a 53.2% rise from $9.5M in FY2024. While gross margin remained strong at 94.2% in FY2025, operating margin was -149.6% and net margin was -436.5%, reflecting a net income of -$63.5M and an EPS of -$0.28. R&D expenses for FY2025 were $17.7M. Over the trailing twelve months, revenue was $13.1M with an operating margin of -834.7% and an EPS of -$0.19. In the latest quarter ended June 30, 2026, quarterly revenue fell 61.3% year-over-year.

As of June 30, 2026, Lineage Cell Therapeutics held $50.8M in cash and short-term investments against total debt of $2.3M, leaving net cash of $48.5M. Liquidity is supported by a current ratio of 6.61 and a debt-to-equity ratio of 0.04 against shareholders' equity of $60.9M. In FY2025, operating cash flow was -$18.9M and free cash flow was -$19.4M. Capital expenditures totaled $522,000, while share buybacks were $16,000. Over the past five years, the company's share count increased 56.0%.

Trading at a last close of $0.98 on October 16, 2026, Lineage Cell Therapeutics has a market cap of $247.4M and an enterprise value of $193.4M. The stock trades at a forward P/E of 30.7x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 18.9x and EV-to-revenue of 14.8x also trade at a premium to the peer median price-to-sales of 4.1x. Over the past year, the stock returned -42.4%, underperforming the S&P 500 (SPY) return of 16.8%, and its 5-year return of -58.3% trails the S&P 500 return of 83.0%.

Wall Street analysts cover the stock with 4 Strong Buy, 2 Buy, and 1 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $5.50, which sits 461.2% above the last close of $0.98. For the fiscal year ending December 31, 2026, analysts estimate revenue of $15.2M and an EPS of -$0.07. For the following fiscal year, 4 analysts estimate revenue of $16.8M and an EPS of -$0.14. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Lineage Cell Therapeutics, Inc. (LCTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LCTX income statement, LCTX balance sheet, LCTX key metrics, LCTX analyst forecast, LCTX chart. See the LCTX stock overview for the latest quote and news.